Literature DB >> 19779298

DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases.

Julie E Ledgerwood1, Barney S Graham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19779298     DOI： 10.4161/hv.8627

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN： 1554-8600


× No keyword cloud information.
  22 in total

1.  Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.

Authors:  Julie E Ledgerwood; Zonghui Hu; Pamela Costner; Galina Yamshchikov; Mary E Enama; Sarah Plummer; Cynthia S Hendel; Lasonji Holman; Brenda Larkin; Ingelise Gordon; Robert T Bailer; Donald M Poretz; Uzma Sarwar; Alisha Kabadi; Richard Koup; John R Mascola; Barney S Graham
Journal:  Contemp Clin Trials       Date:  2015-08-12       Impact factor: 2.226

2.  Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates.

Authors:  Thomas Grunwald; Matthias Tenbusch; Reiner Schulte; Katharina Raue; Hans Wolf; Drew Hannaman; Rik L de Swart; Klaus Uberla; Christiane Stahl-Hennig
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

Review 3.  Advances in structure-based vaccine design.

Authors:  Daniel W Kulp; William R Schief
Journal:  Curr Opin Virol       Date:  2013-06-25       Impact factor: 7.090

4.  Rapid development of a DNA vaccine for Zika virus.

Authors:  Kimberly A Dowd; Sung-Youl Ko; Kaitlyn M Morabito; Eun Sung Yang; Rebecca S Pelc; Christina R DeMaso; Leda R Castilho; Peter Abbink; Michael Boyd; Ramya Nityanandam; David N Gordon; John Robert Gallagher; Xuejun Chen; John-Paul Todd; Yaroslav Tsybovsky; Audray Harris; Yan-Jang S Huang; Stephen Higgs; Dana L Vanlandingham; Hanne Andersen; Mark G Lewis; Rafael De La Barrera; Kenneth H Eckels; Richard G Jarman; Martha C Nason; Dan H Barouch; Mario Roederer; Wing-Pui Kong; John R Mascola; Theodore C Pierson; Barney S Graham
Journal:  Science       Date:  2016-09-22       Impact factor: 47.728

Review 5.  Protein engineering strategies for the development of viral vaccines and immunotherapeutics.

Authors:  Jayne F Koellhoffer; Chelsea D Higgins; Jonathan R Lai
Journal:  FEBS Lett       Date:  2013-10-21       Impact factor: 4.124

6.  Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.

Authors:  B S Graham; R C Kines; K S Corbett; J Nicewonger; T R Johnson; M Chen; D LaVigne; J N Roberts; N Cuburu; J T Schiller; C B Buck
Journal:  Mucosal Immunol       Date:  2010-06-16       Impact factor: 7.313

7.  Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.

Authors:  Jukka Hartikka; Vesselina Bozoukova; Jane Morrow; Denis Rusalov; Mark Shlapobersky; Qun Wei; Sou Boutsaboualoy; Ming Ye; Mary K Wloch; John Doukas; Sean Sullivan; Alain Rolland; Larry R Smith
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

8.  Vaccination with a piggyBac plasmid with transgene integration potential leads to sustained antigen expression and CD8(+) T cell responses.

Authors:  Pietro Bertino; Johann Urschitz; Fukun W Hoffmann; Bo Ra You; Aaron H Rose; Woo Hyun Park; Stefan Moisyadi; Peter R Hoffmann
Journal:  Vaccine       Date:  2014-02-07       Impact factor: 3.641

9.  Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect.

Authors:  Julie E Ledgerwood; Kathryn Zephir; Zonghui Hu; Chih-Jen Wei; Leejah Chang; Mary E Enama; Cynthia S Hendel; Sandra Sitar; Robert T Bailer; Richard A Koup; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  J Infect Dis       Date:  2013-04-30       Impact factor: 5.226

10.  Production of avian influenza virus vaccine using primary cell cultures generated from host organs.

Authors:  Mustafeez Mujtaba Babar; Muhammad Suleman Riaz; Najam-us-Sahar Sadaf Zaidi; Farhan Afzal; Muhammad Sabir Farooq
Journal:  J Ind Microbiol Biotechnol       Date:  2013-03-21       Impact factor: 3.346
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.